Genalive is proud to announce that it has achieved the prestigious Central Board for Accreditation of Healthcare Institutions (CBAHI) accreditation as of December 12, 2023. CBAHI, the official body responsible for healthcare quality in Saudi Arabia, ensures that accredited institutions meet stringent standards in patient care, safety, and operational excellence.
This accreditation demonstrates Genalive’s unwavering commitment to maintaining the highest quality standards in its services. As the largest and first fully localized genetic laboratory in Saudi Arabia, Genalive is dedicated to ensuring that its diagnostic services meet international best practices. By achieving CBAHI accreditation, Genalive has reaffirmed its leadership in the field of genetic testing, providing advanced healthcare solutions tailored to the Saudi community.
CBAHI’s rigorous accreditation process involved an in-depth evaluation of Genalive’s safety protocols, operational systems, and quality management. This milestone highlights Genalive's adherence to globally recognized standards, ensuring that patients receive top-tier, reliable genetic testing and personalized healthcare.
With this accreditation, Genalive continues to lead the way in genetic healthcare, offering innovative and high-quality services that align with Vision 2030’s goal of improving healthcare outcomes across the Kingdom.
For more details about CBAHI accreditation and its significance, visit the CBAHI website.
